A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes

Recruiting now · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Type 1 Diabetes, New Onset

In brief

This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to \<21 with recent-onset stage 3 T1D.

Key facts

Study ID

NCT07061574

Run by

City of Hope Medical Center

People needed

120

Starts

2026-03-10

Expected to finish

2031-04-15

Last updated by the study team

2026-08-04

Who can join

Age: 9 and older, up to 20. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Seattle Children's Hospital — Seattle, Washington, United States (enrolling)
• UCSF — San Francisco, California, United States (enrolling)
• Yale University — New Haven, Connecticut, United States (enrolling)
• University of Florida — Gainesville, Florida, United States (enrolling)
• University of Miami — Miami, Florida, United States (enrolling)
• Indiana University — Indianapolis, Indiana, United States (enrolling)
• University of Minnesota — Minneapolis, Minnesota, United States (enrolling)
• University of Buffalo — Buffalo, New York, United States (enrolling)
• University of Pittsburgh — Pittsburgh, Pennsylvania, United States (enrolling)
• Baylor College of Medicine — Houston, Texas, United States (enrolling)
• Barbara Davis Center for Diabetes University of Colorado Anschutz — Aurora, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.